Each year more than 20 percent of the 3.5 million Americans infected with hepatitis C progress to cirrhosis and ten to fifteen thousand develop end-stage liver disease. Because hepatitis C and HIV disease share common modes of transmission, co-infection occurs in 8-10 percent of all HIV-infected individuals overall and is present in over 70 percent of those with parenteral risk factors. There are few data available on the natural history of HIV and HCV co-infection in specific risk groups, as most previous studies have not assessed the impact of confounding variables such as alcohol use, continuing substance abuse, malnutrition, duration of HCV infection, and degree of HIV-related immune suppression. Moreover, current data regarding the impact of HIV on HCV infection are changing rapidly due to the widespread use of highly active antiretroviral therapy (HAART). New cases of HIV and HCV are expected to continue to occur in substance abusers, since HIV infection is increasing rapidly in inner-city populations. The purpose of this study is to examine the natural history of HIV and HCV co-infection in a large inner city cohort who are predominately minority and have a history of polysubstance abuse. We will compare three groups: 1) HIV and HCV infected, 2) HCV infected alone, and 3) HIV infected alone. Epidemiologic studies will be conducted to explore the risk factors associated with HCV progression, morbidity, and mortality, using both standard clinical parameters and novel surrogate markers of liver fibrosis. Additional targeted substudies will examine the important clinical question of whether therapy of either the HCV or HIV disease alters progression of liver disease. Finally, immunologic studies aimed at increasing our understanding of the pathogenesis of liver injury and why it may be accelerated in HIV disease will be performed. The central hypothesis of this proposal is that alterations in immune function associated with HIV infection are the main determinant of poorer hepatitis C outcomes.
The specific aims of this grant are: 1) to identify the variable(s) that impact the progression of HCV infection in HIV-infected individuals; 2) to determine the effect of HAART on HCV in dually infected persons; and 3) to define the immunologic variables that predict more rapidly progressive liver disease. These studies are expected to improve our understanding of the natural history and pathogenesis of HCV in immunosuppressed hosts.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
3R01DK056410-01S1
Application #
6312305
Study Section
Special Emphasis Panel (ZDK1 (M1))
Program Officer
Hamilton, Frank A
Project Start
1999-09-30
Project End
2004-08-31
Budget Start
2000-03-01
Budget End
2000-08-31
Support Year
1
Fiscal Year
2000
Total Cost
$75,000
Indirect Cost
Name
Boston Medical Center
Department
Type
DUNS #
005492160
City
Boston
State
MA
Country
United States
Zip Code
02118
Baranoski, Amy S; Cotton, Deborah; Heeren, Timothy et al. (2016) Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men. Open Forum Infect Dis 3:ofv214
Nunes, David; Fleming, Catherine; Offner, Gwynneth et al. (2010) Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 105:1346-53
Reed, Carrie; Stuver, Sherri O; Tumilty, Sheila et al. (2008) Predictors of treatment for hepatitis C virus (HCV) infection in drug users. Subst Abus 29:5-15
Graham, Camilla S; Wells, Annalee; Edwards, Erika M et al. (2007) Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J Infect Dis 195:847-56
Solages, Anthony; Vita, Joseph A; Thornton, David J et al. (2006) Endothelial function in HIV-infected persons. Clin Infect Dis 42:1325-32
Nunes, David; Fleming, Catherine; Offner, Gwynneth et al. (2005) HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 40:538-44
Fleming, Catherine A; Tumilty, Sheila; Murray, Jessica E et al. (2005) Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 40 Suppl 5:S349-54
Fleming, Catherine A; Christiansen, Demian; Nunes, David et al. (2004) Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis 38:572-8
Fleming, Catherine A; Craven, Donald E; Thornton, David et al. (2003) Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36:97-100
Hanna, George J; Balaguera, Henri U; Freedberg, Kenneth A et al. (2003) Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis 188:986-91